Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.72
Change (%) Stock is Up 0.04 (2.38%)
Volume81,226
Data as of 03/27/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/16/17Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
‒ NeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 ‒ ‒ Strong Performance in all Areas of the Business in 2016 ‒ ‒ Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) --  Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and co... 
Printer Friendly Version
03/09/17Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
– Data demonstrate Histogenics’ Tissue Engineered Cartilage Constructs Exhibit Mechanical Properties Approaching Native Human Cartilage as Early as Three Weeks in Culture and Prior to Implantation –  – First Study to Use Three Mechanical Tests to Examine and Understand the Performance of Repaired Cartilage in Accordance with FDA Guidance – WALTHAM, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on deve... 
Printer Friendly Version
03/02/17Histogenics Corporation to Announce 2016 Financial Results on March 16, 2017
WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended December 31, 2016, on March 16, 2017 before the market opens.  Histogenics’ management will host a conference call on Thursday, March 16, 2017 at 8:30 a.m. EDT. A question-and-answer session will f... 
Printer Friendly Version
02/23/17Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences.  Cowen and Company 37th Annual Health Care Conference – Boston, MA (March 6-8, 2017) Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Mond... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.